Development of polygenic scores for medication response in diverse populations - polygenic scores (PS) represent an exciting translational application of genomic information that can mitigate some…

Active Project Grant Awarded Last action

Award ID
R21HL168695
Recipient
Awarding agency
Obligated
$652,120

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 73% complete
Originally
Place of performance
East Lansing, MI 48824, USA

Award details come from USAspending.gov.

Description

Development of polygenic scores for medication response in diverse populations - polygenic scores (PS) represent an exciting translational application of genomic information that can mitigate some short comings of traditional genetic approaches, and which have great potential towards understanding and leveraging genetic predisposition to health traits. However, key barriers to clinical application exist, prominently including the fact that current PS were developed nearly exclusively using european individuals. These PS are much less predictive when applied to non-european populations (e.g. african americans). Second is that there has been only very limited application of PS to pharmacogenomics, despite that medication use is arguably the most common and impactful type of medical intervention for patients with common chronic diseases. The goal of this proposed project is to develop novel methods to create and validate PS for african americans that predict medication response in common complex conditions. To accomplish the goal of valid and ancestry robust PS for african americans, we will develop innovative analytic approaches that incorporate localized ancestry to construct PS in a manner that allows for SNP selection and the allelic effect to be dependent on the local ancestry context, thus creating tools that are robust to varying genetic admixture and population structure. We will then compare the performance of these novel tools to two current methods (including state-of-the-art bayesian approaches) within cohorts of african american patients across two different common complex diseases (heart failure and diabetes).

Transactions

Action Obligated Date
Amendment $0
Amendment $202,672
Amendment $202,672
Original award $246,776

Subawards

Subrecipient Amount Awarded
Vanderbilt University Medical Center Dr. Wells and his team will be responsible for all aspects of work at VUMC and production of grantdeliverables. Deliverables will include the creation and… $33,516

Quick answers

Who received award R21HL168695?

R21HL168695 was awarded to Michigan State University by National Heart Lung and Blood Institute (National Institutes of Health) on August 15, 2024.

How much is award R21HL168695 worth?

$652,120 has been obligated on R21HL168695.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award